Viral Vector Market (2026-2036)

The growth of this market is mainly driven by the expansion of the gene and cell therapy clinical pipeline, the growth of commercial chimeric antigen receptor T-cell volumes that consume lentiviral vectors, regulatory flexibility and accelerated review pathways introduced for advanced therapies, process intensification that raises output per batch, and engineered capsids that extend the range of treatable indications. However, falling cost per vector genome that reduces revenue per patient treated, excess contract manufacturing capacity and consolidation among vector manufacturers, clinical and commercial setbacks among approved adeno-associated virus therapies, and the internalisation of vector manufacturing by therapeutic developers restrain the growth of this market.

Furthermore, in vivo gene-modified cell therapy, the movement of gene therapy into larger patient populations beyond rare disease, the expansion of analytical and quality control service demand, and the build-out of Asia-Pacific manufacturing capacity alongside domestic approvals are expected to create significant growth opportunities for the stakeholders in this market.

The Viral Vector Market comprises the production of engineered viral particles used to deliver genetic material into target cells, with the development, analytical and fill-finish services attached to that production. The scope covers adeno-associated virus, lentiviral, adenoviral, retroviral, herpes simplex virus and poxvirus vectors across research, clinical and commercial grades, counted as contract development and manufacturing revenue plus the cost value of production carried out in-house by therapeutic developers and academic centres. The ecosystem spans plasmid and raw material suppliers, cell line, media and transfection reagent providers, bioprocess equipment manufacturers, contract development and manufacturing organisations, analytical and testing laboratories, capsid design companies, and the therapeutic developers, vaccine manufacturers and research institutions that consume vectors.

Several adjacent categories sit outside this market. The finished gene and cell therapy products themselves are excluded, so the revenue of an approved therapy is not counted as vector value. Plasmid DNA supplied as a standalone product, non-viral delivery systems including lipid nanoparticles and electroporation, bioreactors, single-use consumables and analytical instruments are inputs to or adjacent to this market rather than part of it. Viral vector vaccine manufacturing is included, because adenoviral and poxvirus vectors are vector types, and the contraction of that activity after the pandemic is a drag on totals rather than an exclusion.

The demand base for this market is unusually well documented, because the pipeline that will consume vectors is counted. The American Society of Gene & Cell Therapy reported 4,341 gene, cell and RNA therapies in development as of the third quarter of 2025, of which 2,129 were gene therapies including genetically modified cell therapies, or 49% of the total. Within that pipeline, 1,346 programmes were preclinical, 377 in Phase I, 347 in Phase II, 47 in Phase III and 11 at pre-registration, against 38 approved gene therapies. The shape of that distribution matters commercially, because preclinical and early clinical programmes consume small research and toxicology batches while a programme reaching Phase III requires commercial-scale manufacture, process validation and a long-term supply agreement.

Commercial performance among approved adeno-associated virus therapies has been difficult, which is the central reason a measured growth rate is appropriate despite the size of the pipeline. Sarepta Therapeutics reported 2025 total revenue of USD 2,198.2 million, up 16%, with ELEVIDYS net product revenue of USD 898.7 million but fourth-quarter revenue of only USD 110.4 million, a decline of USD 273.8 million year on year, after the company suspended United States shipments to non-ambulatory patients in June 2025 and the FDA approved revised prescribing information in November 2025 adding a boxed warning for serious liver injury and removing the non-ambulatory indication. Novartis reported 2025 Zolgensma sales of USD 1,232 million, up 1% and flat at constant currencies. Pfizer discontinued Beqvez, its approved adeno-associated virus haemophilia B therapy, in February 2025, citing limited demand and clinician engagement, and bluebird bio was taken private by Carlyle and SK Capital in 2025.

Contract manufacturers have responded by retreating from the category. Lonza reported 2025 Specialized Modalities sales declining 3.0% at constant exchange rates with a CORE EBITDA margin of 17.0%, describing Cell and Gene as softer, against Integrated Biologics growth of 32.2% at a 35.3% margin and group sales of CHF 6,531 million, up 19.2%. The contrast between a group growing at 19.2% and a cell and gene platform shrinking isolates the problem to vector demand rather than to contract manufacturing generally. Charles River Laboratories agreed on February 24, 2026 to divest its CDMO and Cell Solutions businesses, representing USD 143 million of 2025 revenue, to GI Partners primarily for future contingent performance-based payments, with sites in Tennessee, Maryland and the United Kingdom supporting viral vector and plasmid DNA production. WuXi AppTec had earlier agreed to sell its United States and United Kingdom advanced therapies operations, five facilities in all, to Altaris.

Specialist vector manufacturing, by contrast, is growing. Oxford Biomedica reported 2025 revenue of GBP 170.9 million on a constant currency basis, up 33% from GBP 128.8 million, with manufacturing services of GBP 81.1 million, development services of GBP 60.1 million and operating EBITDA of GBP 2.3 million against a loss of GBP 15.3 million in 2024. The company reported 48 programmes across 40 clients, contracted client orders of GBP 224 million, lentiviral vector project growth of 34% in the United Kingdom, adeno-associated virus accounting for over half of new client wins, and 2026 guidance of GBP 220 million to GBP 240 million. The divergence between that performance and the retreat of diversified manufacturers indicates that the problem is capacity allocation rather than absent demand.

Manufacturing economics are the dominant force shaping value here, and they move against revenue. Research published in Gene Therapy on July 21, 2026 modelled production at 2,000 litres and reported USD 30.8 per 1 x 10 to the 12th vector genomes for transient transfection, USD 38.6 for baculovirus infection and USD 260.8 for producer cell lines. For a Duchenne muscular dystrophy regimen at 2.8 x 10 to the 15th vector genomes per dose, cost per dose fell from USD 892,000 at 50 litres to USD 86,000 at 2,000 litres on scale alone, and transfection optimisation reduced a USD 458,000 baseline at 2,000 litres to USD 42,000, a reduction of roughly 91%. Perfusion intensification before and after transfection delivered USD 82,000 per dose. Combined, the paper reported 70 to 150-fold reductions in cost per dose.

The commercial consequence is that this market sells less value per patient treated each year. Titres in the same work rose from a transient transfection benchmark of 6.0 x 10 to the 10th vector genomes per millilitre to 9.4 x 10 to the 11th with perfusion before and after transfection, while patient coverage from a single 2,000 litre batch rose from 8 patients to 116 with transfection optimisation and 123 with perfusion intensification. A manufacturer that once sold fifteen batches to treat a cohort now sells one. Growth in patients treated is therefore offset substantially by output growth per batch, which is why a pipeline of 2,129 gene therapy programmes supports a forecast CAGR in the low double digits rather than the rate that pipeline count alone would imply.

Capsid engineering compounds that effect while expanding the market in another direction. Dyno Therapeutics announced two new capsids at the American Society of Gene & Cell Therapy annual meeting on May 13, 2026, reporting that Dyno-n96, an optimised AAVrh74-based muscle capsid, achieved efficient delivery at 5.2 x 10 to the 12th vector genomes per kilogram, approximately 25-fold lower than reported doses for certain existing muscle gene therapies, and that Dyno-bn8 transduced up to 88% of skeletal myofibres in primates at the same dose. A 25-fold dose reduction removes 25-fold of demand per patient. It also makes feasible indications that were previously impossible on manufacturing grounds, because a systemic dose that could not be produced at acceptable cost becomes routine, which is how the market grows even as value per patient falls.

Regulatory conditions have improved. The FDA announced a flexible approach to chemistry, manufacturing and control requirements for cell and gene therapies on January 11, 2026, stating that it would not require overly stringent comparability data for minor manufacturing changes, would consider flexibility on release specifications, and that sponsors need not manufacture three process performance qualification lots. On April 23, 2026 the agency granted accelerated approval to Otarmeni, a dual adeno-associated virus serotype 1 vector therapy from Regeneron for sensorineural hearing loss linked to biallelic OTOF variants, 61 days after biologics licence application filing under the national priority voucher pilot and the first gene therapy approved under that programme. Each of these reduces the manufacturing and timeline burden that has slowed programmes toward approval.

Vector type demand is diverging by application. Adeno-associated virus dominates the in vivo pipeline and carries far larger doses, with the Gene Therapy work estimating annual global vector genome demand of 8.0 x 10 to the 13th for RPE65 retinal dystrophy against 2.8 x 10 to the 18th for spinal muscular atrophy, 5.7 x 10 to the 18th for haemophilia B, 1.7 x 10 to the 19th for Duchenne muscular dystrophy and 7.6 x 10 to the 19th for haemophilia A, a spread of six orders of magnitude between a subretinal and a systemic indication. Lentiviral vectors serve ex vivo gene-modified cell therapy at far smaller volumes per patient but against commercial products with growing volumes, which is why lentiviral demand is advancing while high-dose adeno-associated virus programmes contend with safety and reimbursement constraints.

Over the forecast period, market value is expected to grow from USD 4.40 billion in 2026 to USD 11.85 billion in 2036. Growth is led by pipeline progression toward approval, commercial cell therapy volumes, regulatory flexibility, analytical demand and Asia-Pacific capacity, and is moderated by falling cost per vector genome, excess manufacturing capacity, setbacks among approved adeno-associated virus therapies and the internalisation of production by sponsors. The resulting CAGR of 10.4% reflects a market in which the number of patients supplied rises considerably faster than the value of the vectors supplying them.